Peter Mac proudly hosts the first ProsTIC Preceptorship this week, in partnership with the Prostate Cancer Foundation of Australia and the Prostate Cancer Foundation.

Over 300 attendees from 29 nations have registered to attend the two day event, which is exploring the latest in research, case studies, practical applications, and the future of PSMA (prostate-specific membrane antigen) imaging and theranostics.

Theranostic treatment for prostate cancer involves targeting a prostate specific membrane antigen (PSMA) on cancer cells. This is done by first using a radioactive molecule to reveal the cancer’s spread via a scan. A similar radioactive molecule is then used to kill cancer cells.  

Peter Mac has been pioneering in this space for almost a decade.

Experts from Peter Mac’s world-leading Prostate Theranostics Imaging Centre of Excellence (ProsTIC) are leading sessions, joined by multidisciplinary colleagues from Australia and around the world. 

International speakers include Professor Thomas Hope (US), Professor Sillke Gillessen (Switzerland), and Professor Veeru Kasivisvanathan (UK).

The Preceptorship supports the ProsTIC program’s goal of delivering up to date education for doctors, scientists, patients and the community.

It will conclude on Saturday afternoon with a free consumer-focused education session. Consumers must register here to attend.

Delivered both online and in person, the consumer session will provide an overview of PSMA theranostics, followed by the experiencers of two consumers, and an opportunity to ask the experts.

See the full ProsTIC Preceptorship 2022 program here:

More information on PSMA theranostics at Peter Mac is available here: